Daratumumab for kidney disease caused by abnormal proteins
Treatments studied
Part of Blood & lymphatic, Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if daratumumab can help people with a kidney condition called MGRS, where abnormal proteins damage the kidneys. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- Your kidney biopsy shows MGRS (a type of kidney disease from abnormal proteins).
- You have significant protein in your urine (≥500 mg per day) or your kidney function is at least 20 ml/min.
- You have not had certain chemotherapies recently (like cyclophosphamide within 6 months, or high-dose steroids within 6 weeks).
- You do not have active infections like HIV, hepatitis B or C (or they are well controlled).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) for people with rare kidney diseases caused by abnormal plasma cells. It aims to see if this treatment can help control the disease and protect kidney function.
This Phase 2 study tests daratumumab (an immune-targeting medicine) in people with PGNMID, a kidney disease where abnormal immune proteins build up in the kidney filters. It aims to reduce harmful protein in the urine and improve kidney health.
This trial tests a combination of four drugs (CyBorD plus daratumumab) to treat kidney damage caused by abnormal proteins (monoclonal gammopathy). It aims to improve kidney function and reduce protein levels.
This trial tests whether daratumumab can help treat a type of rejection that happens more than a year after a kidney transplant. It may be an option for people who have biopsy-proven antibody-mediated rejection and new donor-specific antibodies.
This trial tests the drug daratumumab in people newly diagnosed with light chain amyloidosis that affects the heart, kidney, or liver. The goal is to see if daratumumab can help control the disease. Eligibility depends on your disease stage and overall health.
This Phase 2 trial studies daratumumab (an antibody medicine) for adults whose rare lymph node/immune-related cancers have come back or did not respond to treatment. It may help shrink disease and improve symptoms, including for people living with HIV when their virus is well controlled.
Hear when a new Kidney Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.